Recovery
BPC-157 and TB-500 are among the most studied peptides in preclinical musculoskeletal and tissue repair research. Human clinical trial data is limited — the studies below are primarily preclinical animal models.
5 referenced studies
The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration
Chang CH, et al. · Journal of Applied Physiology, 2011 · PMID 21030672
Demonstrates BPC-157 accelerating tendon fibroblast migration and survival in Achilles tendon models, with dose-dependent effects on cell movement.
BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing
Sikiric P, et al. · Current Pharmaceutical Design, 2018 · PMID 29998800
Reviews BPC-157's role in angiogenesis and tissue healing across multiple tissue types including gastrointestinal, tendon, and muscle.
Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats
Japjec M, et al. · Biomedicines, 2021 · PMID 34829776
Documents BPC-157 restoring myotendinous junction function and reversing muscle atrophy in injury models.
Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications
Goldstein AL, et al. · Expert Opinion on Biological Therapy, 2012 · PMID 22074294
Comprehensive review of thymosin beta-4 biological activities including wound healing, cell migration, anti-inflammatory effects, and clinical application potential.
Thymosin beta4 and cardiac repair
Shrivastava S, et al. · Annals of the New York Academy of Sciences, 2010 · PMID 20536454
Demonstrates thymosin beta-4 inhibiting myocardial cell death, stimulating vessel growth, and activating cardiac progenitor cells in injury models.
Performance
CJC-1295 and Ipamorelin are among the most studied growth hormone secretagogues, with human clinical trial data including the studies below.
3 referenced studies
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog
Ionescu M, Frohman LA. · Journal of Clinical Endocrinology and Metabolism, 2006 · PMID 16352683
Human study showing CJC-1295 maintains pulsatile GH secretion patterns while significantly elevating IGF-1 levels over extended periods.
Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of growth hormone-releasing hormone, in healthy adults
Teichman SL, et al. · Journal of Clinical Endocrinology and Metabolism, 2006 · PMID 16849409
Human clinical trial documenting sustained GH and IGF-1 elevation over multiple days following CJC-1295 administration in healthy adults.
Ipamorelin, the first selective growth hormone secretagogue
Raun K, et al. · European Journal of Endocrinology, 1998 · PMID 9849822
Establishes ipamorelin as a selective GH secretagogue with minimal effects on cortisol and prolactin — a key differentiator from earlier secretagogues.
Metabolic
AOD-9604 is a synthetic fragment of human growth hormone studied for its selective lipolytic effects. The studies below are primarily preclinical. AOD-9604 completed Phase II clinical trials but was discontinued for lack of sufficient weight-loss efficacy at clinical endpoints.
2 referenced studies
The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta3-AR knock-out mice
Heffernan MA, et al. · Endocrinology, 2001 · PMID 11713213
Demonstrates AOD-9604 reducing body fat in obese animal models through beta-3 adrenergic receptor pathways without affecting blood glucose or IGF-1 levels.
Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone
Ng FM, et al. · Hormone Research, 2000 · PMID 11146367
Characterizes AOD-9604 as a GH fragment that stimulates fat breakdown while showing no significant effect on blood sugar or insulin sensitivity.
Regenerative
GHK-Cu is a naturally occurring human tripeptide first identified in 1973. KPV is a tripeptide derived from alpha-MSH. Both have extensive preclinical literature. Human data is limited primarily to topical applications for GHK-Cu.
5 referenced studies
Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data
Pickart L, Margolina A. · International Journal of Molecular Sciences, 2018 · PMID 29986520
Reviews GHK-Cu's role in activating genes associated with tissue repair, collagen synthesis, antioxidant defense, and anti-inflammatory signaling across more than 4,000 human genes modulated.
GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration
Pickart L, et al. · BioMed Research International, 2015 · PMID 26236730
Examines GHK-Cu's role in skin regeneration pathways, documenting its effects on collagen synthesis, metalloproteinase activity, and cellular remodeling.
Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+
Maquart FX, et al. · FEBS Letters, 1988 · PMID 3169264
Original study documenting GHK-Cu stimulating collagen synthesis in human fibroblast cultures at nanomolar concentrations — the foundational collagen research for this peptide.
PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation
Dalmasso G, et al. · Gastroenterology, 2008 · PMID 18061177
Demonstrates KPV inhibiting NF-kB and MAP kinase inflammatory pathways at nanomolar concentrations, with oral administration reducing colitis incidence in animal models.
Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis
Xiao B, et al. · Molecular Therapy, 2017 · PMID 28143741
Shows KPV reducing intestinal inflammation and accelerating mucosal healing in colitis models, with targeted nanoparticle delivery increasing efficacy 12,000-fold over free solution.
Cognitive
Selank and Semax were developed by the Russian Academy of Sciences. Semax is approved in Russia for stroke and neurological conditions. Most studies are from Russian clinical and preclinical research. Large-scale Western randomized controlled trials are limited.
3 referenced studies
Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia
Zozulia AA, et al. · Zhurnal Nevrologii i Psikhiatrii, 2008 · PMID 18454096
Clinical study of 62 patients showing Selank produced anxiolytic effects comparable to medazepam while also demonstrating antiasthenic and psychostimulant effects without sedation.
Functional Connectomic Approach to Studying Selank and Semax Effects
Melik-Kasumov T, et al. · Frontiers in Neuroscience, 2020 · PMID 32342318
fMRI study in 52 healthy participants documenting distinct effects of Selank and Semax on functional connectivity between the amygdala and temporal cortex regions involved in anxiety regulation.
Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus
Dolotov OV, et al. · Brain Research, 2006 · PMID 16996037
Documents Semax producing a 1.4-fold increase in hippocampal BDNF protein and 3-fold increase in BDNF mRNA, with treated animals showing improved conditioned avoidance learning.
A note on evidence levels
The majority of peptide research cited on this page comes from preclinical animal studies. Human clinical trial data is limited for most of these compounds outside of CJC-1295, Ipamorelin, and Semax. Elyvate does not claim these studies prove efficacy in humans. Our physicians review each intake individually and prescribe based on their clinical judgment, not on marketing claims.
Ready to discuss these protocols with a physician?
Check my eligibility →